Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion

NCT06180499 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT06180499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06180499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
March 31, 2024
Completion date
September 30, 2029
Enrollment
27 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancies, regulatory t cell depletion, relapse